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Bromochloromethane (BCM) is a volatile compound and a by-product of disinfection of water by chlorination. Physiologically
based pharmacokinetic (PBPK) models are used in risk assessment applications. An updated PBPK model for BCM is generated
and applied to hypotheses testing calibrated using vapor uptake data. The two diﬀerent metabolic hypotheses examined are (1) a
two-pathway model using both CYP2E1 and glutathione transferase enzymes and (2) a two-binding site model where metabolism
can occur on one enzyme, CYP2E1. Our computer simulations show that both hypotheses describe the experimental data in a
similar manner. The two pathway results were comparable to previously reported values (Vmax = 3.8mg/hour, Km = 0.35mg/liter,
and kGST = 4.7/hour). The two binding site results were Vmax1 = 3.7mg/hour, Km1 = 0.3mg/hour, CL2 = 0.047liter/hour. In
addition, we explore the sensitivity of diﬀerent parameters for each model using our obtained optimized values.
1.Introduction
Bromochloromethane (BCM, CH2BrCl, CAS number
83847-49-8) is a volatile solvent historically used in portable
ﬁre extinguishers. BCM was gradually replaced by halons
in the 1970s and banned in 2002 due to its ozone depletion
potential. However, BCM is still used as an intermediate
in the production of other solvents [1] and is rapidly
absorbed via inhalation due to its volatility [2]. Similar to
other halomethanes, there is a suggestion of hepato- and
nephro-toxicity due to prolonged exposure [2]. Another
potential source of exposure for BCM is through oral
ingestion via water, since BCM is considered a water
disinfection byproduct [3], and is listed within the U.S.A
EPA’s Candidate Contaminant List (CCL). Additional
research on brominated disinfection by-products (DBPs)
has been proposed because there is evidence that brominated
species can be more potent than chlorinated compounds [4].
Theoccurrenceofbrominateddisinfectionby-products(e.g.,
bromochloromethane) is an added consideration for coastal
areas due to potential bromine intrusion from seawater
and subsequent transformation of chlorinated by-products
into brominated species [5]. Given the potential health
impact of brominated chemicals, we chose to study BCM
in consideration of both increased potential for exposure
near coastline utilities, and on the basis of a deﬁciency and
availability of published data. Based on a recent PubMed
search, the published literature for BCM is much less than
that of the well-studied bromodichloromethane (BDCM,
CHBrCl2, CAS number 75-27-4), another structurally
related DBP.
Physiologically based pharmacokinetic (PBPK) models
are computational tools that are increasingly used to address
risk assessment issues, particularly in quantifying the rela-
tionship between measures of external exposure and internal
dose [6]. PBPK models are sets of equations representing
the ﬂow of blood and toxicant into and out of organs
and body tissues. Unlike classical pharmacokinetic models,2 Journal of Toxicology
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Figure 1: Schematic representation of BCM metabolism, adapted from [13].
PBPK models include species-speciﬁc physiological, chemi-
cal, and biochemical parameters, allowing for extrapolation
to humans [7]. The interaction between modelers and
biologists is crucial in determining the ﬁnal representation
of organs to ensure inclusion of target organs, special
physicochemical properties and toxicity. An accurate math-
ematical description of biological processes (i.e., an accurate
model) requires synthesis of mathematics, modeling, and
systems biology. The expectation of such an approach is
that an integrated modeling eﬀort and its application to
quantiﬁcation of health risk assessment would increase our
conﬁdence in the simulated results.
For volatile halogenated methanes, metabolism is an
important component studied to provide explanations of
how toxicity occurs. The complex kinetics suggested for
dihalomethane metabolism (e.g., BCM) consists of two
components:asaturableMichaelis-Mentenhyperbolasuper-
imposed with a linear pathway [9]. This linear pathway does
not appear to saturate and shows a continued proportional
increase at higher exposure concentrations. At lower concen-
trations, the contribution of this linear pathway is smaller
than that of the saturable component. The question becomes
whatarethephysiologicalcounterpartsofthesetwodiﬀerent
metabolism components? What enzymes may exhibit such
diﬀerentcharacteristics?PreviousPBPKmodeling workwith
dichloromethane (DCM, CH2Cl2, CAS number 75-09-2) led
to the hypothesis that two diﬀerent enzymes are involved in
its metabolism: CYP2E1, a P450 isoenzyme, and GST (GSH
S-transferase). The early PBPK modeling work was followed
by experiments showing that the GST pathway, although
numerically small, was an important pathway toxicologi-
cally. Based on experimental evidence, the GST pathway is
believed to be responsible for the carcinogenicity of these
compounds [15]. The early PBPK modeling paved the way
for establishing a two-pathway hypothesis which includes
both P450 and glutathione transferase (GST) enzymes [9].
Based on these concepts, the proposed metabolic scheme
for bromochloromethane is shown in (Figure 1). Speciﬁcally
for BCM, the two-pathway hypothesis was ﬁrst suggested by
PBPK modeling followed by experimental conﬁrmation of
adduct formation from the GST pathway in bacterial assays
[16]. Using an in vitro Salmonella assay, BCM was conﬁrmed
to be mutagenic in the presence of cytosol (GST containing
fraction) relative to other structurally related halomethanes
[17]. Based on structural similarity with other brominated
ethanes (i.e., 1,2-dibromoethane), where plasma bromide
was used to track metabolism, the existence of a small but
relevant GST pathway is to be expected for BCM [18].
However, we were not able to ﬁnd in vivo studies that can
be used to quantify the linear pathway for BCM, other than
suggestions that in vivo data is lacking [13].
Other than having two diﬀerent enzymes describe the
complex kinetics, is there another plausible explanation for
the linear kinetics exhibited by the in vivo closed chamber
data? If so, can PBPK modeling be used to explain the
additional linear kinetics? In recent years, the realization has
been made that several P450s may exhibit atypical kinetics,
that is, complex kinetics that cannot be explained by the sin-
gle saturable Michaelis-Menten kinetics [19]. In an attempt
to better describe these increased complexities, biochemical
models with two sites have been developed to describe the
linear kinetics exhibited at higher concentrations [20]. These
complexbiochemicalmodelshaveanadditionalbindingsite,
which is simultaneously available to the substrate (Figure 2).
Once binding to the second site occurs, a conformational
change takes place that modiﬁes the metabolism of the
ﬁrst site. We propose that a PBPK model for BCM can be
constructed to show the plausibility of a second site model.
At this point in time, we are not suggesting that one kinetic
model is more realistic than the other, but are investigating
the possibility of alternative pathways based on atypical
kinetics and its implications for metabolism. Interestingly,
onepotential waytodistinguish betweenthetwomechanism
is by the type of metabolites excreted. With two-sites in a
single enzyme, the metabolites produced would probably be
reactive products of CYP2E1 oxidation. In contrast, a two-
pathway mechanisms would have glutathione containing
metabolites during excretion.Journal of Toxicology 3
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Figure 2: Comparison of single-sited and two-sited kinetics, adapted from [14].
When testing a new hypothesis using PBPK model
simulations, one possible question becomes how to rank
the importance of relative metabolic parameters. We believe
that this question is particularly relevant when trying to
distinguishbetweenmetabolicconstantsthatarenumerically
small. Sensitivity analysis is a mathematical tool that allows
determination of how the change in one parameter aﬀects
model predictions. When conducting sensitivity analysis,
the model is run repeatedly to determine how changes
in parameter values relate to changes in a prediction.
Although optimization is performed before sensitivity anal-
ysis, modeling behavior insights come from the sequential
sensitivity analysis. The sensitivity analysis results will also
be dependent on the values obtained from the optimization.
Both techniques are combined since the ﬁrst is needed to
ﬁnd the “correct” parameter values, while sensitivity analysis
looks for impact across parameters. In the present work,
both techniques were used to identify potential issues with
metabolic parameter quantiﬁcation. Once the optimization
is performed, sensitivity analysis can determine if a unique
set of values exist for the optimized results. In general,
sensitivity analysis has been used in combination with
PBPK modeling to estimate the relative ranking of diﬀerent
model parameters [21], sometimes including the interaction
betweenparameters[22].Localsensitivityanalysisisthesim-
plest form of sensitivity analysis, which allows for estimation
of the impact of each parameter individually. One potential
analogy is that this type of sensitivity analysis is similar to
a worst-case scenario estimate for the variability of each
parameter. In addition to ease of implementation, another
advantage of this analysis is its ability to sort potential
identiﬁability issues, or to state whether the optimization
provides unique estimates for the resulting values obtained
for the diﬀerent modeling hypotheses.
In summary, the goals of this study were (1) to use PBPK
modeling in combination with BCM closed chamber data
to test two potential metabolic hypotheses: a two-pathway
enzyme combination of CYP2E1 and GST and a one enzyme
mechanism consisting of two binding sites for CYP2E1; (2)
to make use of sensitivity analysis to identify important
model parameters; (3) to compare the ﬁts across diﬀerent
metabolic hypotheses and suggest future experiments that
lead to increased conﬁdence in our simulations.
2. Methods
2.1. PBPK Models
2.1.1. Closed Chamber Data. Inhalation closed chamber data
for BCM in rats were obtained from the published litera-
ture [9] digitized using UN-SCAN-IT 6.0 (Silk Scientiﬁc,
Orem, UT, USA). Inhalation closed chamber data were
collected from a sealed system, allowing for quantiﬁcation of
metabolism. A BCM bolus was injected into the chamber at
time zero. After equilibrium between the rat and air inside
the chamber, BCM decreased with time as it was distributed
into tissues and metabolized by the rodent. A PBPK model
was then constructed to describe the decline in air chamber
concentration. The metabolic parameters were calculated
using optimization techniques in combination with the
inhalation data. Diﬀerent metabolic hypotheses were inves-
tigated by using a PBPK model with the closed chamber-
derived metabolic parameters to predict metabolism.
2.1.2. Core Model. A ﬂow-limited PBPK model based on
the structure described by Ramsey and Andersen [23]w a s
used to describe BCM metabolism (Figure 3). A seven-
compartment model (lung, blood, adipose, rapidly per-
fused tissue, slowly perfused tissue, liver, and kidney) was
developed for BCM, with the assumption that metabolism
occurred via the same enzymes in liver and kidney. All
physiological parameters were obtained from the literature
as shown in Table 1 .D i ﬀerential equations based on mass
conservation principles were derived for each organ. Lung
and blood compartments use a steady state assumption, sim-
plifying the overall solutions for the model. Tissue to blood
partition coeﬃcients were calculated using experimentally-
derived BCM coeﬃcients from Gargas et al., 1986 [9]
(described in the appendix). After derivation, all equations
were coded into MatLab (MathWorks, version 7.11.0.584)
using the equation solver ode15s.4 Journal of Toxicology
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Figure 3: Schematic representation of PBPK model used for BCM.
Table 1: Parameters for adult Fisher 344 rats and corresponding signiﬁcance in the PBPK model. (Note: partition coeﬃcients are unitless
[8].)
Parameter Signiﬁcance Value Source
Miscellaneous
BW Body weight 0.25kg [9]
QCC Cardiac output 15L/hr/kg
0.75 [10–12]
loss Chamber loss rate 0.025 (1/hr) [9]
N Number of rats 3 [9]
Vcha Chamber volume 9 (L) [9]
Flow rates (L/hr)
QV Ventilation/perfusion rate 1.7 [12]
q1 Rapidly perfused blood ﬂow rate QV −

qi

qi is the sum of other compartments
q2 Blood ﬂow fraction to adipose 0.082 [11]
q3 Blood ﬂow fraction to slowly perfused 0.257 Muscle+bone+skin values from [11]
q4 Blood ﬂow fraction to kidney 0.138 [11]
q5 Blood ﬂow fraction to liver 0.242 [11]
Partition coeﬃcient
Part Blood/air 41.5 [9]
Pliv Liver/blood 0.7 [9]
Prap Rapidly perfused/blood 0.7 Assumed to be same as liver
Pkid Kidney/blood 0.7 Assumed to be same as liver
Pslow Slowly perfused/blood 0.267 Muscle [9]
Padi Adipose/blood 7.8 [9]
Volume (L)
Vslow Volume fraction for slowly perfused 0.674 [11]
Vliv Volume fraction for liver 0.044 [11]
Vkidney Volume fraction for kidney 0.0075 [11]
Vadi Volume fraction for adipose 0.112 [11]
Vrap Rapidly perfused 0.91 −

Vi
Total vol. — sum of all other
compartments. Blood is 9% of BWJournal of Toxicology 5
2.1.3. Metabolic Hypotheses Testing. The current work tested
two diﬀerent metabolic hypotheses using the same basic
PBPK model structure, varying only the equations for liver
and kidney metabolism. Previously, Gargas et al. [9]e v a l -
uated typical Michaelis-Menten kinetics, with metabolism
described by a single CYP2E1 binding site. The results
of their simulations demonstrated that the addition of a
linear term was necessary to describe the closed cham-
ber data. Thus, a two-pathway model with two diﬀer-
ent enzymes, CYP2E1 exhibiting Michaelis-Menten kinetics
and GST exhibiting linear kinetics, provided much better
ﬁts to the data than the model that incorporated only
Michaelis-Mentenkinetics[9].Here,thetwo-pathwaymodel
(Michaelis-Menten and GST) described by [9]i sc o m p a r e d
to the two-binding site model described by Evans and
Caldwell [24]. In the two-binding site model, a modiﬁed
Michaelis-Menten equation that includes two binding sites
for CYP2E1 is used to describe BCM metabolism.
2.1.4. Two-Pathway Kinetics. The two-pathway description
uses Michaelis-Menten kinetics in addition to a linear term
to account for GST metabolism. The equations listed below
represent the additional metabolic term in both the liver
(Metl) and the kidney (Metk). Liver is set to account for
94.8% of total body metabolism and the kidney 5.2% based
on [25]:
Metl = 0.948

Vmax[Cliv]
Km +[Cliv]
+kGST[Cliv]Vliv

,
Metk = 0.052

Vmax[Ckid]
Km +[Ckid]
+kGST[Ckid]Vkid

,
(1)
where (i) Vmax: maximum velocity of the reaction, mg/hour,
(ii) Km:a ﬃnity constant, mg/liter, (iii) kGST: proportionality
constant for linear pathway metabolized by glutathione
transferase, /hour.
2.1.5. Two-Binding Site Kinetics. Linear kinetics at higher
concentrations can also be described using a dual binding
site, as demonstrated for dichloromethane using closed
chamber data [24]. In this case, CYP2E1 undergoes a struc-
tural change in which two separate binding sites are simulta-
neously available to BCM, and metabolism is achieved with
one enzyme. For the dual binding site equation, the squared
concentration term becomes asymptotically linear at higher
exposure concentrations. This squared term is not present
in the typical Michaelis-Menten equation and will lead to
ad i ﬀerent rate of ascent to the asymptote. The modiﬁed
Michaelis-Menten equation reﬂecting two binding sites in
one enzyme [20]b e c o m e s
Metl = 0.948

Vmax1[Cliv]+C L 2[Cliv]
2
Km1 +[Cliv]

,
Metk = 0.052

Vmax1[Ckid]+C L 2[Ckid]
2
Km1 +[Ckid]

,
(2)
where (i) Vmax1: maximum metabolic rate for the ﬁrst
binding site, mg/hour. The second binding site is accounted
forbyCL2,(ii)Km1:aﬃnityconstantfortheﬁrstbindingsite,
mg/liter, (iii) CL2: clearance constant consisting of the ratio
of the maximum metabolic rate and the aﬃnity constant,
Vmax2/Km2, for second binding site, liter/hour.
2.2. Comparison of the Diﬀerent Metabolic Models. At o t a l
of six metabolic parameters were optimized using ﬁve
closed chamber data sets, each having a diﬀerent starting
concentration. Optimizations were performed using the
natural log of the data with MatLab’s fminsearch func-
tion (MathWorks, version 7.11.0.584). For the two-pathway
model, three parameters were optimized using the digitized
data: Vmax, Km,a n dkGST. For the two-binding site model,
three parameters were optimized using the digitized data:
Vmax1, Km1, and CL2.T h ef u n c t i o nfminsearch, available in
the standard MatLab package, tries to minimize a “cost” as
the minimum diﬀerence between data and simulation. The
best overall ﬁt minimized by fminsearch includes the entire
data range (200–4000ppm).
2.3. Physiological Value Selection. The physiological values to
be used in the PBPK model have been updated from those
used in the original simulations of the data in 1986. As an
example, cardiac output values for F344 rats are now avail-
able [11]. The range of normalized cardiac output values for
F344 rats values (QCC) is between 10–20 liters/hour/kg
0.75,
due to dependence of cardiac output on age. We decided
to use the mean value of 15 liters/hour/kg
0.75, since a 225g
rat is considered adult [10]. The ventilation rate for rats
was calculated using the ventilation perfusion ratio, which
varies between 1–4 fold due to diﬀerences in measurement
methodology [22, Table 31]. Since the mean value of 15
liters/hour/kg
0.75 matched the values used in the benzene
PBPKmodeldatedfromapproximatelythesametimeperiod
as the Gargas dataset, we used the same ventilation perfusion
rate as in Medinsky et al. [12] for consistency. The F344-
speciﬁc tissue perfusion and volume values were adopted
from [11].
2.4. Sensitivity Analysis. Sensitivity coeﬃcients were calcu-
lated with partial derivatives for each variable of interest
with respect to the model parameter being speciﬁed in
the model. Sensitivity coeﬃcients were then normalized by
both the variable and model parameter. The resulting time
course for each sensitivity coeﬃcient was plotted. Sensitivity
coeﬃcients were calculated using Automated Diﬀerentia-
tion written by Martin Fink and available at MatlabCen-
tral (http://www.mathworks.com/matlabcentral/). Another
Matlab function written by Adam Attarian (tssolve NC
State University, Raleigh, NC, USA) was used to organize
the partial derivatives and for the ﬁnal plots. A three-
dimensional surface was generated to show variation in
sensitivity coeﬃcients with time, and variability within the
metabolic parameter. These tests were performed to check
stability of the sensitivity coeﬃcients when introducing
variability around the optimized estimates.6 Journal of Toxicology
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Figure 4: PBPK modeling results using two diﬀerent metabolic hypotheses. (a) shows results for the two-pathway model. (b) shows results
for the two-binding site model.
Table 2: Optimized parameter results.
Two-pathway model Two-binding site model
Vmax 3.8mg/hour Vmax1 3.7mg/hour
Km 0.35mg/liter Km1 0.3mg/liter
kGST 4.5/hour CL2 0.047 liter/hour
3. Results
The optimization results are shown in Table 2.F o ra l l
concentrations studied, the two-pathway and two-binding
site models gave very similar descriptions of the closed
chamber data (Figure 4). Both the Vmax and Km values are
similar for the two-pathway and two-binding models. The
two-pathway parameter values were as follows:
Vmax = 3.8mg/hour,
Km = 0.35mg/liter,
kGST = 4.7/hour.
(3)
The two-binding site hypothesis uses Michaelis-Menten
parameters Vmax1 and Km1 to describe the ﬁrst site, and
clearance CL2, deﬁned to be the ratio of Vmax2 and Km2,f o r
the second site. The two-binding site results were as follows:
Vmax1 = 3.7mg/hour,
Km1 = 0.3mg/liter,
CL2 = 0.047 liters/hour.
(4)
When comparing the values for both metabolic hypotheses,
Michaelis-Menten results for the two-binding site hypothesis
are very similar to the Michaelis-Menten values for the two-
pathway hypothesis. The Vmax and Km values are similar for
the two pathway and two-binding models. Based on these
results, both metabolic hypotheses are considered equally
plausible.
Normalized sensitivity coeﬃcients for all model parame-
ters were calculated after optimization results were obtained.
The majority of resulting sensitivity coeﬃcients were not
shown, since we are focusing on metabolic parameters:
Vmax, Km, kGST,o rC L 2. The authors performed sensitivity
analysis using 500ppm as the initial concentration. Each
sensitivity ﬁgure consists of two panels. The ﬁrst panel
presents sensitivity coeﬃcients calculated for the impact of
air chamber concentration on the simulated value of Vmax
and the second panel presents sensitivity coeﬃcients for liver
concentration of BCM. Figure 5 presents sensitivity results
for the two-pathway model. The sensitivity coeﬃcients for
Vmax havethehighestvalues.TheVmax sensitivitycoeﬃcients
for liver concentration are larger than those obtained
using chamber air as the experimental variable. Figure 6
presents sensitivity results for the two-binding site model.
The sensitivity coeﬃcients for Vmax also have the highest
values, particularly when comparing liver coeﬃcients versus
chamber air coeﬃcients. For both model hypotheses, peak
Vmax sensitivity occurs within the ﬁrst two hours.
A three-dimensional plot of liver sensitivity coeﬃcients
forthetwo-pathwaymodelispresentedinFigure 7.Thethird
dimensionrepresentsvariabilityinVmax generatedbyrepeat-
ing sensitivity analysis simulations that vary Vmax between
2.5–4.5mg/hour (to include the mean value 3.8mg/hour).
Based on the value of Vmax, there is a peak in sensitivity to
Vmax occurring within the ﬁrst 3 hours. The chamber airJournal of Toxicology 7
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concentration plot shows a much shallower surface, with no
obvious peaks in sensitivity towards Vmax shown.
4. Discussion
RiskassessmentsforvolatilechemicalshaveusedPBPKmod-
els to account for diﬀerences across routes and extrapolate
from rodent experiments to human populations [26, 27].
The use of a PBPK model allows for the integration of
physiological, chemical, and biochemical information with
diﬀerent kinetic hypotheses. Closed chamber inhalation data
are a measure of total rate of metabolism represented by
the decrease in the concentration of the volatile chemical
inside the chamber after a bolus injection. One application
of closed chamber inhalation data in combination with
PBPK modeling has been the suggestion of metabolic
hypotheses leading to eﬀects in a target organ, particularly
for halomethanes [9, 28]. In this context, PBPK models
have been proposed as useful computational tools for risk
assessments.
PBPKmodelshaveplayedadecisiveroleinthesuggestion
of an in vivo role for the GST pathway (two-pathway model)
and its contribution to toxicity for halogenated compounds
[15, 28]. In the case of DCM, the GSH conjugation pathway
has a small proportionality constant (∼0.01/hour [24]),
while the GST pathway for BCM is larger (∼5.3/hour [9]).
Following the inclusion of a linear pathway in the PBPK
model for halogens, in vitro work in bacterial systems
provided the ﬁrst evidence that GST was the enzyme
associated with the additional linear pathway. In vitro work
also suggested that as the number of bromines included
in the compound increased, the resulting genotoxicity was
larger. For example, Thier et al. [16] demonstrated that
the genotoxicity of CH2Cl2 (DCM) was less than that of
CH2ClBr (BCM), which was less than that of CH2Br2
(dibromomethane)toxicity.Priortotheseexperiments,there
was no experimental evidence that dihalomethanes such
as BCM were metabolized via a GST pathway. The only
suggestion for the existence of this second pathway came
from PBPK modeling and closed chamber data.
The current PBPK model making use of a two-pathway
mechanism gives a similar kGST value to that of previous
models (Table 2 versus [9, 29, 30]). (It is important to note
that both PBPK models in [29, 30]w e r eb a s e do n[ 9].
In addition, the Vmax and Km values are slightly diﬀerent
when compared to [9]: 2.57mg/hour and 0.3mg/liter,
resp.). We attribute the diﬀerence in optimized values to
diﬀerences in physiological constants used in our model.
The current PBPK model made use of F344 speciﬁc values
[11], which correlates to the strain used in the closed
chamber experiments. It is important to note that the F344
physiological values were not available at the time when
the ﬁrst BCM model was published (1986). The largest
diﬀerences in volume or ﬂow for the compartments used
in the two diﬀerent BCM PBPK models probably lie in
the lumped compartments, namely, the rapidly and slowly
perfused compartments.
To our knowledge, there is no previous PBPK work that
makes use of a two-binding site mechanism for BCM, mak-
ing a comparison of our linear CL2 constant with previous
models not possible. An important realization of this PBPK
modeling eﬀort is that both metabolic hypotheses appeared
equallyplausible.Inordertohelpconvinceourselvesthatthis
wasthecase,theavailableBCMinvivoliteraturewasstudied.
Early in vivo experiments with halomethanes conﬁrmed the
enzymatic role for GST for other iodinated or brominated
compounds but not for BCM [31]. This paper refers to
earlier work and states that speciﬁcally for BCM, a BCM-
GST reaction is not present in measurable amounts. This
early indication concludes that GST is not involved as a
major component of BCM metabolism. Another indication
that the GST pathway is very small in vivo comes from the
vapor uptake experiments, where treatment with pyrazole
almost completely suppressed BCM metabolism as shownJournal of Toxicology 9
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Figure 8: BCM vapor uptake with pyrazole treatment [9].
in Figure 8,f r o m[ 9]. Since CYP2E1 has been shown to be
the major P450 contributing to its oxidative metabolism
[32], the in vivo metabolic decrease observed at this high
concentration argues for the predominance of CYP2E1 over
other P450s. In addition, the in vitro kinetic values reported
by [16] also suggest a small kinetic constant when compared
to ethylene dibromide or dibromomethane. The ability to
numerically estimate metabolic constants for the linear
pathway using sensitivity analysis will be discussed later.
Several P450s (2A1, 2B1, and 2E1) have shown atypical
kinetics, explained by allosteric mechanisms making use of
as e c o n ds i t ea tl e a s tin vitro [33]. Li et al. [33]p e r f o r m e d
simulations to conﬁrm the relative small size of CYP2E1’s
active site, stating that for this enzyme the reaction proceeds
by the cooperative binding of two substrates simultaneously
to form a ternary complex. The substrate that binds in the
active site is usually called active substrate, while the other
one that binds in the eﬀector site, and that controls the
oxidation of the active substrate is called eﬀector substrate
[33].
Eﬀector substrates are becoming increasingly studied to
oﬀer potential explanations for drug-to-drug interactions.
CYP2E1 speciﬁcally plays a diverse role in physiology,
toxicity, and metabolism. For example, CYP2E1 is a P450
isoform with an important role in glycogenesis, and its
physiological role is increasingly being recognized [34]. At
present, this isoform is known to metabolize about 70 diﬀer-
ent compounds of varying size, including alcohols, ketones,
nitrosamines, anesthetics, and even long-chain fatty acids.
One of the questions recently resolved by studying human
CYP2E1 structure is based on addressing how is it possible
for this enzyme, with a small active site, to metabolize
substrates ranging in a wide number of sizes (including fatty
acids). In fact, it is the suggestion of a channel structure
available as a second site, and in proximity to the active site,
that becomes a solution to help explain CYP2E1’s ﬂexibility
to accommodate diﬀerent sized substrates [35]. Although
BCM is a small molecule, probably able to ﬁt in the active
site,theexistenceofasecondsitedoesdescribelinearkinetics
at higher exposure concentrations. The second site model
thus became a candidate for inclusion in a PBPK model
calibrated using in vivo data for BCM. Since the second
binding site in CYP2E1 is involved in fatty acid metabolism,
we propose that BCM binding to this second site may impair
fatty acid metabolism and may indirectly prevent normal
metabolismoflargermoleculesthatmaybealreadyimpaired
in chronic illnesses such as diabetes. This proposed eﬀect is
hypothesized to occur in addition to the glutathione-based
toxicity based on a two-pathway hypothesis.
When using optimization to estimate metabolic model
parameters, correlation can be an important issue that
may impact the ability to estimate unique values for the
parameters. Basic algebra reminds us that a system of
equations can be uniquely solved when the number of
parameters is equal to the number of equations, assuming
that the estimates are independent of each other. In general,
the unique estimation of Km will depend on having an
independent estimate for Vmax. Since Km is interrelated to
Vmax, experiments with multiple concentrations are needed,
and the concentrations used must be high enough that
metabolic saturation is reached.
One of the applications of local sensitivity analysis is to
help illustrate the existence of these potential correlations
between parameters because this aﬀects the ability to solve
for unique estimates. For more complex metabolic models,
the relationship between metabolic parameters may not be
obvious. Sensitivity analysis theory states that parameters
are uniquely identiﬁable when the sensitivity coeﬃcients
cannot add to zero [36]. For example, if all sensitivity
coeﬃcients examined are positive, then their sum cannot be
equal to zero. Using this reasoning, these authors examined
the time course plots for 500ppm and the sensitivity
coeﬃcients for both metabolic hypotheses. The sensitivity
coeﬃcients can be estimated for the diﬀerent variables
included in the model, allowing the analysis to suggest
improvements in the experimental design. For this reason,
liver concentration was selected as a possible experimental
variable. When compared with chamber concentration, liver
concentration resulted in increased sensitivity towards Vmax.
Since sensitivity coeﬃcients for other metabolic parameters
were nearly zero, Vmax is uniquely identiﬁable when using
closed chamber experiments. At higher concentrations, the
sensitivity coeﬃcients for both kGST or CL2 increase with
exposure time (results not shown). This current sensitivity
analysis corroborates the importance of these two additional
parameters at higher concentrations.
We utilized a method using local sensitivity analysis as
an initial step to help determine identiﬁability issues. When
unique identiﬁability is guaranteed, the ability to have one
unique solution is also guaranteed. Therefore, local sensi-
tivity analysis can be seen as a ﬁrst step towards increasing
our conﬁdence in the parameters obtained as a solution.
The results of our sensitivity analysis suggest that measuring
liver concentration would provide improved estimates for
Vmax at intermediate concentrations and improved estimates
for the linear constants kGST or CL2 at high concentra-
tions. To combat uncertainty in the estimates for Vmax
and other metabolic parameters, we implemented a novel10 Journal of Toxicology
approach by estimating the three-dimensional surface for
the sensitivity coeﬃcient changing with time, and including
variability in the metabolic estimate of concern. If future
experiments include liver concentration measurements, our
three-dimensional analysis at 500ppm suggests that peak
information on Vmax occurs before 2 hours, suggesting that
experiment duration can be shortened by several hours. The
application of PBPK modeling and three-dimensional sen-
sitivity analyses can be helpful to design future experiments
aimed at reﬁning metabolic estimates.
The combination of optimization and sensitivity analysis
presented in this paper also leads to diﬀerent suggestions
for future experimental design. In vivo experiments using
the vapor uptake approach take advantage of a non-
invasive approach to estimate Vmax and Km by using air
chamber concentration. However, the current sensitivity
analysis suggests an increased advantage to using in vitro
approaches to estimate metabolic parameters. The sensitivity
analysis performed consistently indicates that liver tissue
measurements increase our ability to estimate Vmax and
kGST for the two-pathway hypothesis. The same sensitivity
analysis tools also indicate that our ability to estimate Vmax1
and CL2 for two-binding site hypothesis is similar to that
for the two-pathway hypothesis. The sensitivity analysis for
liver tissue concentration also suggests a peak or maximum
ability to estimate Vmax for an experiment taking 2 hours
(instead of 6). Future experiments can include the possible
combination of in vivo and in vitro vapor uptake techniques
performed using intermediate concentrations just above and
below metabolic saturation (500ppm in this case).
Future in vivo research is needed to answer deﬁnitely
the question as to whether BCM’s atypical metabolism
can be described by a two diﬀerent enzymes or by one
enzyme with multiple binding sites. In this paper, we have
used PBPK modeling to demonstrate the plausibility of
both mechanisms in describing a linear kinetic pathway at
higher concentrations. In order to determine if two separate
enzymes are involved, a pharmacological agent can be used
to deplete the GST pathway to determine if metabolism
can proceed without GSH conjugation. As an example,
suchexperimentshavebeenperformedfordichloromethane,
using phorone as an pharmacological agent leading to GSH
depletion [37]. These experiments were performed in vitro,
using microsomes harvested from the GSH-depleted animals
and used with vial equilibration techniques (to determine
total changes in amount metabolized in vitro). Based on
their results, the GST pathway was a small quantitative
c o m p o n e n to ft h et o t a la m o u n tm e t a b o l i z e d .B a s e do n
calculations provided by the current PBPK model, the GST
pathway is expected to be less than 5% of the total amount
metabolized. This small percent of amount metabolized
diﬀerence is what is being described as either GST- or
CYP2E1-dependent. In order to experimentally measure the
diﬀerence in GST-mediated metabolism, a pharmacological
agent such as phorone could be used for the next series
of closed-chamber experiments and compared to BCM
exposure without the phorone exposure. The diﬀerence
between the two experiments would provide the actual
diﬀerence in total metabolism observed between the two
pathways.
As stated before, closed chamber inhalation experiments
quantify changes in total chemical disappearance; thus, addi-
tional experiments are necessary to identify the actual P450
isoform involved in BCM metabolism. The conﬁrmation
of CYP2E1 as being the major P450 involved for in vivo
BCM metabolism was obtained by using diﬀerent P450
speciﬁc inhibitors and inducers to examine diﬀerences in
CO production [32]. The use of inhibitors has become an
important experimental tool to discern kinetic mechanisms
involved in metabolism of diﬀerent P450 isoforms. Pyrazole
(CAS number 288-13-1), and its derivatives have been,
used as CYP2E1 inhibitors by measuring total metabolic
disappearance in microsomal fractions [38]. Recently, a
structurally analog of pyrazole, 4-methylpyrazole or (4-MP),
has been used to describe its CYP2E1 inhibition properties
using a second-site kinetic mechanism [14]. These authors
explained the inhibitory mechanism for 4-MP by adding
a second-site to ﬁt the experimental results using pNP (4-
nitrophenol, CAS number 100-02-7) oxidation as a marker
for CYP2E1 activity [39]. Future in vivo closed chamber
experiments can make use of the in vitro paradigm used by
[14] in that increasing pyrazole concentrations can be used
to distinguish between the single-site or double-site models.
These proposed experiments would add a dose response
element to the single dose pyrazole inhibition experiments
already performed by [9] as shown in Figure 8. A PBPK
model can then be used to describe the resulting pyrazole
inhibitionaseithercontainingasingleordoublesiteenzyme.
In summary, a combination of closed chamber data and
PBPK modeling was used to examine diﬀerent metabolic
descriptions for BCM. The standard two-pathway descrip-
tion was compared to a two-binding site model within
the same enzyme. Metabolic parameters for the diﬀerent
descriptions were optimized using the gas uptake data
for BCM. Diﬀerent metabolic parameters have diﬀerent
concentration ranges that determine their ability to be
measured, and sensitivity analysis was used to demonstrate
identiﬁabilityrelationshipsbetweenparameters.Thebeneﬁts
of these computational tools towards improved health risk
assessments rely on their ability to accurately describe
metabolic hypotheses.
5. MatLab Codes
There are three distinct sections to the code used to generate
the results found in this paper. These sections are Data
Transformations and Initialization, Compartmental Models,
and Sensitivity Analysis. In addition to the brief descriptions
below, each function has an extensive help section at the
top of each m ﬁle. Note that the names of the functions are
italicized for clarity.
5.1. Data Transformations and Initialization. Almost all of
the codes used for modeling require access to physiological
parametersandthedataset;thescriptﬁleparamswritesthese
parameters into the working directory as well as converts theJournal of Toxicology 11
original data (in parts per million) to a form usable by the
model (in mg/liter). Note that params is called before any
o t h e rf u n c t i o na si tg e n e r a t e sa .mat ﬁle containing relevant
parameters called by the other functions in the model.
5.2.CompartmentalModels. Theheartofthecompartmental
model is ode15s, a stiﬀ ordinary diﬀerential equation (ODE)
solverpartofthestandardMatLabpackage.Thereareseveral
functions that build upon the output from the ODE solver.
The main ﬁle, BCMmain, allows the user to choose to
optimize for the metabolic parameters or to use the inputted
values to plot the original data concentrations (in ppm)
versus the model curves on a logarithmic scale.
BCMmain, when used strictly as a plotting tool, is self-
contained (aside from calling the ﬁle generated by params
and the ODE solver). In addition to a plot output, BCMmain
also outputs a string containing the absolute root mean
square error (rmse) and the relative rmse for the ﬁt of each
model at each concentration. The absolute error is calculated
by comparing the two-norm of the vector containing the
diﬀerence between the model predictions and the given
data divided by the number of elements in the vector. The
relative rmse error is given by the absolute error at each
concentration divided by the initial concentration. This gives
a sense of the percent error in the model.
When choosing to optimize for metabolic parameters,
BCMmain calls on the function optthis, which uses a combi-
nation of fminsearch and a least-squares method to optimize
for the parameters. The function fminsearch, available in the
standard MatLab package, tries to minimize a “cost”; we
deﬁne this cost to be the sum of the diﬀerence (obtained by
linear-least squares) between the model predictions and data
ateachconcentration.TheequationsforthePBPKmodelare
contained in the ﬁle pbpk, which is called upon by the ODE
solver and the curve-ﬁtting functions. The output of optthis
is the vector of metabolic parameters that yields the best ﬁt
(afteraspeciﬁednumberofiterations)usedtoplotthemodel
in BCMmain.
5.3. Sensitivity Analysis. There are two main functions used
for the sensitivity analysis aspect of the code. The ﬁrst
function, plot2dsens takes in user-speciﬁed parameters and
plots the sensitivity of these parameters in the chamber and
the liver compartments. We choose these compartments due
to their importance in obtaining data from the chamber as
a noninvasive way; however data obtained from the liver
may yield more insight. A second function, plot3dsens,a n d
its associated helper function modelchoice,a r ed e s i g n e dt o
give a three-dimensional plot that shows the sensitivity of
one parameter with respect to time as it varies over a user-
input range in each compartment of interest. This analysis
divides up the range of the parameter of interest into a
user-speciﬁed number of subintervals and calculates the
sensitivity of the parameter using the subinterval value as the
parameter value in the same sense as the two-dimensional
model. The sensitivity plots are then spliced together into a
three-dimensional plot.
Both sensitivity functions require the use of tssolve,
created by Adam Attarian (North Carolina State University,
http://www4.ncsu.edu/∼arattari/) ,w h i c hi nt u r nr e q u i r e s
Martin Fink’s myAD package. Both functions are available
from the MathWorks website (http://www.mathworks.com).
5.4. Code Evaluation. One of the questions addressed in the
present work is how to validate new code that is generated to
study a chemical, such as the case for BCM. These authors
approached this question on several fronts. First, a search
was made for existing code using a similar chemical to BCM.
The previously published DCM model [24] was selected for
a comparison with BCM. The DCM code was converted
to model BCM by changing chemical-speciﬁc parameters
to reﬂect those of BCM. The simulations were performed
using the BCM/DCM version. Results of these simulations
were then compared with the newly created BCM code
and found to be identical. Once the new BCM code was
veriﬁed to be correct, the second step was to optimize
for the parameters describing two-pathway kinetics and
determine their similarity with previously published values
(see Results). This additional step ensures that the new PBPK
model description accurately depicts BCM metabolism.
Appendix
The diﬀerential equations used to describe each compart-
ment in the PBPK model were developed using the law
of conservation of mass: the amount of BCM ﬂowing into
each compartment must equal the amount of BCM leaving
the compartment, whether it is through blood ﬂow or
ventilation, or through loss by metabolism or condensation.
The following abbreviations can be found in Table 1:
dAven
dt
= q1Crap + q2Cadi + q3Cslow
+ q4Ckid + q5Cliv
−QCC ·Cven,
(A.1)
=⇒ Cven =
q1Crap + q2Cadi + q3Cslow + q4Ckid + q5Cliv
QCC
,
(A.2)
dAlung
dt
= QCC ·Cven +QV ·Cinh,
−Cart

QCC +

QV
PBld

,
(A.3)
=⇒ Cart =
QCC · Cven +QV · Cinh
QCC +QV/PBld
,( A . 4 )
Cexh =
Cart
PBld
,( A . 5 )
dAinh
dt
= N ·QV ·(Cexh −Cinh) −loss · Ainh,( A . 6 )
dArap
dt
= q1 ·

Cart − Crap

,( A . 7 )12 Journal of Toxicology
dAadi
dt
= q2 · (Cart −Cadi),( A . 8 )
dAslow
dt
= q3 · (Cart −Cslow),( A . 9 )
dAkid
dt
= q4 · (Cart −Ckid) −MetK, (A.10)
dAliv
dt
= q5 · (Cart −Cliv) −MetL. (A.11)
For (A.1)–(A.11), we denote the venous concentration
of BCM leaving a speciﬁc compartment comp as Ccomp =
Acomp/(Vcomp ·Pcomp), where Acomp is the amount of BCM in
the compartment, Vcomp is the volume of the compartment,
and Pcomp is the partition coeﬃcient for the compartment.
Note there is no associated partition coeﬃcient for the
chamber, thus the concentration in the chamber is denoted
by Cinh = Ainh/Vcha. Partition coeﬃcients (given in Table 1)
describe the measure of the diﬀerential solubility of BCM
as the chemical passes between two diﬀerent phases; this
unitless ratio accounts for the amount of BCM absorbed
by compartmental tissue as it passes from the compartment
back into the bloodstream. Previous studies have determined
the tissue/air and blood/air partition coeﬃcients for BCM
[9]. To determine the tissue/blood partition coeﬃcient for
each compartment, (A.12)i su s e d :
Porgan = tissue : blood =
tissue : air
blood : air
. (A.12)
Several assumptions were made for the construction of each
equation in the system: Initially, a diﬀerential equation,
(A.1), was created to represent the amount of BCM in
the venous compartment. However, simulations in MatLab
demonstrated that the amount of BCM in the venous
compartment approached equilibrium very quickly with
respect to the length of the experiment. This allowed us to
set (A.1) equal to zero to obtain an algebraic expression
for the concentration of BCM in the venous compartment
with respect to the concentration of BCM in the other
compartments. A similar technique was used with the lung
compartment (A.3), obtaining an algebraic expression for
the concentration of BCM in the arterial compartment.
List of Abbreviations
Chemicals
4-MP: 4-methylpyrazole
BCM: Bromochloromethane
BDCM: Bromodichloromethane
DBP: Disinfection by-products
DCM: Dichloromethane
GST: Glutathione transferase
PBPK: Physiologically-based pharmacokinetic
model
CCL: Candidate Contaminant List, Oﬃce of
Water, US EPA.
Equation Variables
Vmax: Maximum metabolic rate, mg/hour
Vmaxi: Maximum metabolic rate for binding
site i in two-binding site hypothesis,
mg/hour
Km:A ﬃnity constant, mg/liter
Kmi:A ﬃnity constant for binding site i in
two-binding site hypothesis, mg/liter
kGST: Proportionality constant for linear
pathway metabolized by GST, /hour
CL2: clearance constant consisting of the
ratio of the maximum metabolic rate
and the aﬃnity constant, Vmax2/Km2,
for second binding site, liter/hour
Acompartment: Amount of BCM in compartment
Pcompartment: Partition coeﬃcient for compartment
Vcompartment: Volume of compartment, liters
Ccompartment: Concentration of BCM in
compartment, given by
Ccomp = Acomp/(Vcomp ·Pcomp).
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